Safety and Tolerability of Antiretrovirals during Pregnancy. (28th March 2011)

• Record Type: Journal Article
• Authors: Weinberg, Adriana; Forster-Harwood, Jeri; Davies, Jill; McFarland, Elizabeth J.; Pappas, Jennifer; Kinzie, Kay; Barr, Emily; Paul, Suzanne; Salbenblatt, Carol; Soda, Elizabeth; Vazquez, Anna; Levin, Myron J.
• Other Names: Gravett Michael G. Academic Editor.
• Is Part Of: Infectious diseases in obstetrics and gynecology. Volume 2011(2011)
• Publication Date: 2011-03-28
• Subjects: Generative organs, Female -- Infections -- Periodicals; Communicable diseases in pregnancy -- Periodicals; 618.142005
• DOI: 10.1155/2011/867674
• Languages: English
• ISSNs: 1064-7449

Abstract

Abstract : Combination antiretroviral therapy (CART) dramatically decreases mother-to-child HIV-1 transmission (MTCT), but maternal adverse events are not infrequent. A review of 117 locally followed pregnancies revealed 7 grade ≥3 AEs possibly related to antiretrovirals, including 2 hematologic, 3 hepatic, and 2 obstetric cholestasis cases. A fetal demise was attributed to obstetric cholestasis, but no maternal deaths occurred. The drugs possibly associated with these AE were zidovudine, nelfinavir, lopinavir/ritonavir, and indinavir. AE or intolerability required discontinuation/substitution of nevirapine in 16% of the users, zidovudine in 10%, nelfinavir in 9%, lopinavir/ritonavir in 1%, but epivir and stavudine in none. In conclusion, nevirapine, zidovudine, and nelfinavir had the highest frequency of AE and/or the lowest tolerability during pregnancy. Although nevirapine and nelfinavir are infrequently used in pregnancy at present, zidovudine is included in most MTCT preventative regimens. Our data emphasize the need to revise the treatment recommendations for pregnant women to include safer and better-tolerated drugs.